Biographical Info

Lien vers site personnel

CV

Elias Fattal est professeur de Pharmacotechnie à l’Université Paris-Saclay et a été président de l’APGI de 2003 à 2010. Il a obtenu le diplôme de Docteur en  pharmacie (1983) et le Doctorat en Sciences (1990) au sein de l’université Paris-Sud et a été interne en Pharmacie des hôpitaux de l’inter région Nord-Ouest (1984-1986). Après avoir réalisé un post-doctorat à l’Université de Californie à San Francisco (1990-1991), il devient Maître de Conférences (1992) et Professeur à l’Université Paris-Saclay (2000). Il a dirigé l’Institut Galien Paris-Saclay (2010-2019). Au cours des 30 dernières années, il a fortement contribué aux domaines de l’administration de médicaments en utilisant les nanotechnologies pour l’administration ciblée ou locale de substances actives. Il a développé un axe scientifique autour de la nanotoxicité pulmonaire et la conception de systèmes d’administration à base de nanoparticules pour l’administration de médicaments anti-inflammatoires et d’acides nucléiques. L’un de ses brevets a abouti à Calixarene® Cevidra, une crème pour le traitement de la contamination externe par les actinides. Il a contribué à environ 300 publications et chapitres de livres. Le professeur Fattal a reçu le Pharmaceutical Sciences World Congress (PSWC) Research Achievement (2007), le Controlled Release Society Fellow Award (2016), En 2016, un prix lui a été décerné par l’Académie des sciences pour ses recherches à l’interface de la chimie et de la biologie et plus récemment en 2018, il a reçu le Prix Maurice-Marie Janot. Il siège au comité de rédaction de plusieurs revues scientifiques et est membre de l’Académie nationale de pharmacie, de l’Académie nationale de médecine et de l’Académie européenne des sciences (EURASC).

Elias Fattal is a full professor in Drug Delivery Science at the University of Paris-Saclay and has been president of APGI from 2003 to 2010. He received his Pharmacy Degree (1983) and Ph.D. (1990) from the University of Paris-Sud and followed an internship in Hospital Pharmacy (1984-1986). After visiting the Department of Pharmaceutical Chemistry at the University of California, San Francisco, for a post-doctoral position (1990-1991), he became an Associate Professor (1992) and full Professor at the University of Paris-Saclay (2000). He has been the head of the Institut Galien Paris-Saclay (2010-2019). Over the past 30 years, he has made fundamental and applied contributions to the fields of drug delivery using nanotechnologies for targeted or local drug delivery. He has recently focused on lung nanotoxicity and the design of nanoparticle-based delivery systems to deliver anti-inflammatory drugs and nucleic acids. One of his patents led to Calixarene® Cevidra, a cream for treating external actinide contamination. He has contributed to around 300 publications and book chapters. Prof. Fattal has received the Pharmaceutical Sciences World Congress (PSWC) Research Achievement (2007), the Controlled Release Society fellow award (2016), was awarded in 2016 by the French Academy of Sciences for his research at the interface of chemistry and biology and more recently in 2018 received the Maurice-Marie Janot Award. He serves on the editorial board of several scientific journals. He is a member of the National Academy of Pharmacy, the National Academy of Medicine, and the European Academy of Sciences.

Mots clés

Administration pulmonaire, acides nucléiques, inflammation, cancer, aptamères, nanotoxicologie

Lung delivery, nucleic acids, inflammation, cancer, aptamers, nanotoxicology

10 publications majeures

• Yu Z, Tsapis N, Fay F, Chen L, Karpus A, Shi X, Cailleau C, García Pérez S, Huang N, Vergnaud J, Mignani S, Majoral JP, Fattal E. Amphiphilic Phosphorus Dendrons Associated with Anti-inflammatory siRNA Reduce Symptoms in Murine Collagen-Induced Arthritis. Biomacromolecules, 24, 2, 667–677, 2023.
• Pinheiro do Nascimento L, Tsapis N, Reynaud F, Desmaële D, Moine L, Vergnaud J, Abreu S, Chaminade P, Fattal E. Mannosylation of budesonide palmitate nanoprodrugs for improved macrophage targeting. European Journal of Pharmaceutics and Biopharmaceutics, 170:112-120, 2022.
• Simón-Vázquez R, Tsapis N, Lorscheider M, Rodríguez A, Calleja P, Mousnier L, de Miguel Villegas E, González-Fernández Á, Fattal E. Improving dexamethasone drug loading and efficacy in treating arthritis through a lipophilic prodrug entrapped into PLGA-PEG nanoparticles. Drug Delivery and Translational Research, 2022. Drug Delivery and Translational Research volume 12, pages 1270–1284, 2022.
• Japiassu KB, Fay F, Marengo A, Louaguenouni Y, Cailleau C, Denis S, Chapron D, Tsapis N, Nascimento TL, Lima EM, Fattal E. Interplay between mucus mobility and alveolar macrophage targeting of surface-modified liposomes. Journal of Controlled Release, 352, 15-24, 2022.
• Bohr, A, Tsapis, N, Foged, C, Andreana, I, Yang, M, Fattal, E, Treatment of acute lung inflammation by pulmonary delivery of anti-TNF-alpha siRNA with PAMAM dendrimers in a murine model. European journal of pharmaceutics and biopharmaceutics, 156, 114-120, 2020.
• Fattal, E, Fay, F, Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases. Advanced drug delivery reviews, 175, 113809, 2021.
• Costamagna F, Hillaireau H, Vergnaud-Gauduchon J, Clarisse D, Jamgotchian L., Loreau O, Denis S, Gravel E, Doris E, Fattal E. Nanotoxicology at the particle/micelle frontier: influence of core-polymerization on the intracellular distribution, cytotoxicity and genotoxicity of polydiacetylene micelles. Nanoscale, 12, 2452-2463, 2020.
• Lorscheider M., Tsapis N., Ur-Rehman M., Gaudin F., Stolfa I., Abreu S., Mura S., Chaminade P., Espeli M., Fattal E., Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis. Journal of Controlled Release, 296 179-189, 2019.
• Alshaer, W, Hillaireau H, Vergnaud J, Mura S, Deloménie C, Sauvage F, Ismail S, Fattal E. Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model. J Control Release, 271:98-106, 2018.
• Bohr A, Tsapis N, Andreana I, Chamarat A, Foged C, Delomenie C, Noiray M, El Brahmi N, Majoral JP, Mignani S, Fattal E. Anti-inflammatory effect of anti-TNF-α siRNA cationic phosphorous dendrimers nanocomplexes administered intranasally in a murine acute lung injury model. Biomacromolecules, 18 (8), 2379–2388, 2017.